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ABSTRACT
Introduction: The aim of this study was to
assess the impact of baseline characteristics on
visual outcome of patients with diabetic
macular edema and compare the results of
clinical trials with different patient populations.
Methods: A model was created with
patient-level data from the RESPOND/
RESTORE trials to estimate the impact of
baseline characteristics on increases in
best-corrected visual acuity (BCVA) with
anti-vascular endothelial growth factor
therapies, measured by letters gained on the
Early Treatment Diabetic Retinopathy Study
scale from baseline to month 12. Mean BCVA
gains with ranibizumab 0.5 mg pro re nata or
laser photocoagulation monotherapy were
predicted, assuming baseline characteristics
equivalent to those in the VIVID-DME/
VISTA-DME trials. These results were compared
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with the gain with aflibercept 2.0 mg every
8 weeks in VIVID-DME/VISTA-DME. Sensitivity
analyses assessed outcome robustness.
Results: Baseline BCVA and central retinal
thickness differed significantly between trials.
In unadjusted data, patients in RESPOND/
RESTORE receiving ranibizumab gained an
additional 6.6 letters [95% confidence interval
(CI): 4.5–8.7] compared with patients receiving
laser monotherapy. After adjusting data to
assume baseline characteristics equivalent to
VIVID-DME/VISTA-DME, patients receiving
ranibizumab were predicted to gain an
additional 9.9 letters (95% CI: 7.3–12.4)
compared with those receiving laser
monotherapy. These results were similar
(0.1-letter difference in favor of aflibercept;
95% CI: -2.9 to 3.2; P = 0.94) to the gain in
BCVA in patients receiving aflibercept in
VIVID-DME/VISTA-DME compared with those
receiving laser monotherapy (10.0 letters,
95% CI: 8.3–11.7).
Conclusion: After adjusting for baseline
characteristics, the difference in letters gained
between patients receiving ranibizumab versus
aflibercept was non-significant across trials,
highlighting the importance of adjusting for
baseline characteristics in future comparisons.
Funding: Novartis Pharma AG.
Keywords: Aflibercept; Diabetic macular
edema; Ophthalmology; Ranibizumab;
Vascular endothelial growth factor
INTRODUCTION
Diabetic macular edema (DME) is a frequent
manifestationofdiabetic retinopathy thatoccurs
when the retina swells owing to fluid leakage
from the macular capillary bed [1, 2]. DME can
lead to visual impairment and, if left untreated,
blindness. It is associated with reductions in
health-related quality of life and can result in a
substantial socioeconomic burden [3, 4].
Until recently, laser photocoagulation
monotherapy was the standard of care for
DME. Laser monotherapy provides vision
stabilization in patients with DME, but offers
limited clinically significant improvements in
vision [5]. Anti-vascular endothelial growth
factor (VEGF) treatments have become
available and are now the standard of care for
these patients, offering a better prognosis [6].
Ranibizumab, an anti-VEGF-A agent, was the
first therapy to receive approval for the
treatment of DME [approved by the European
Medicines Agency (EMA) in January 2011] [7].
Another anti-VEGF agent, aflibercept, was
approved by the EMA for this indication in
August 2014 [8].
The approved regimens in the European
Union of ranibizumab 0.5 mg pro re nata (PRN)
and aflibercept 2.0 mg every 8 weeks have not
been compared directly in the same clinical trial.
The only study comparing ranibizumab with
aflibercept in patients withDME is theDRCR-net
Protocol T trial (ClinicalTrials.gov identifier:
NCT01627249) [9]. In Protocol T, patients
receiving aflibercept gained, on average,
2.1 letters more than patients receiving
ranibizumab (P = 0.03). Importantly, that study
used a dose of ranibizumab (0.3 mg PRN) that is
lower than the dose approved outside theUnited
States (0.5 mg PRN). Therefore, the relative
effects of ranibizumab 0.5 mg PRN and
aflibercept 2.0 mg every 8 weeks remain
unclear. In fact, the National Institute for
Health and Care Excellence considered that
‘‘the results (of Protocol T) could not be
considered in its decision making’’ when
appraising ranibizumab 0.5 mg PRN versus
aflibercept 2.0 mg every 8 weeks [10]. Therefore,
we performed a cross-trial, indirect comparison
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incorporating patient-level statistical modeling
to compare the visual outcomes of these two
treatment regimens. We used clinical trials that
compared ranibizumab 0.5 mg PRN (RESPOND
[11] and RESTORE [12]; ClinicalTrials.gov
identifiers: NCT01135914 and NCT00687804,
respectively) or aflibercept 2.0 mg every 8 weeks
(VIVID-DME and VISTA-DME; ClinicalTrials.gov
identifiers: NCT01331681 and NCT01363440,
respectively) [13] with laser monotherapy.
Table 1 shows the reported increases in
best-corrected visual acuity (BCVA) for each
trial, as measured by a gain of letters on the
Early Treatment Diabetic Retinopathy Study
scale [14]. The description of each trial can be
found in the online supplementary material.
METHODS
A methodology similar to that described here
has been used in a previous indirect comparison
study [15]; this approach represents a robust
procedure for comparing ranibizumab and
aflibercept for the treatment of DME. The
basic idea behind the model was to leverage
the patient-level information in RESPOND/
RESTORE to determine the relationships
between baseline characteristics, treatment
and BCVA change from baseline to month 12.
Once those relationships had been established,
one could predict the outcome of the
RESPOND/RESTORE clinical trials if the
patients had different baseline characteristics
to those in the actual trials.
Base Case Model (Model 1)
The analysis consisted of four steps.
Step 1: Identification of Confounders
Published literature was used to identify
baseline characteristics considered most likely
Table 1 Mean gain in BCVA (number of letters) from baseline to month 12, as reported in each of the four published trials
RESPOND [11], RESTORE [12], VIVID-DME, and VISTA-DME [13]
Trial Comparators Mean number of letters gained (SD)
Anti-VEGF monotherapya Laser monotherapy
RESPOND [11] Ranibizumab 0.5 mg PRN
Laser
7.5 (12.1) -0.5 (13.4)
RESTORE [12] Ranibizumab 0.5 mg PRN
Laser
6.8 (8.3) 0.9 (11.4)
VIVID-DME [13] Aﬂibercept 2.0 mg every 8 weeks
Laser
10.7 (9.3) 1.2 (10.6)
VISTA-DME [13] Aﬂibercept 2.0 mg every 8 weeks
Laser
10.7 (8.2) 0.2 (12.5)
For all reported results, missing data were handled using the last observation carried forward approach. For RESTORE,
VIVID-DME, and VISTA-DME, patient data in this table match the published data [12, 13]. The published data for
RESPOND were based on only patients who had measurements at month 12, and showed a mean BCVA gain at month 12
of 8.9 letters for ranibizumab monotherapy and 0.3 letters for laser monotherapy [11]
BCVA best-corrected visual acuity, PRN pro re nata, SD standard deviation, VEGF vascular endothelial growth factor
a Either ranibizumab or aﬂibercept, depending on the trial
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to predict a gain in BCVA at 12 months.
Predictors reported to correlate negatively with
a gain in BCVA included baseline BCVA [16],
central retinal thickness (CRT) [17], and age
[16]. Baseline BCVA and CRT differed
significantly between RESPOND [11]/RESTORE
[12] and VIVID-DME/VISTA-DME [13] (Table 2);
these factors were included in the base case
model. Age was excluded because mean age did
not differ significantly between patients in
RESPOND/RESTORE and VIVID-DME/
VISTA-DME (Table 2). In RESTORE, it was
shown that the impact on the outcomes of
some baseline characteristics, especially CRT,
was different between patients receiving
ranibizumab and those receiving laser [12].
Therefore, this model also included interaction
terms between baseline characteristics and
treatment.
Step 2: Regression Model
The RESPOND and RESTORE patient-level data
were appended. A patient-level model analyzed
change in BCVA from baseline to month 12 as a
function of the baseline values:
Yi ¼ b0 þ b1ranibizumabi þ b2ranibizumab
þ laseri þ b3BCVAi þ b4CRTi þ b6BCVAi
 ranibizumabi þ b7CRT ranibizumabi
þ b8BCVAi  ranibizumabþ laseri þ b9CRT
 ranibizumabþ laseri
Here, Yi represents the change in BCVA from
baseline to month 12 [last observation carried
Table 2 Baseline data for RESPOND [11], RESTORE [12], VIVID-DME, and VISTA-DME [13]









n 191 286 183 286
BCVA, letters 64.1 (10.3) 59.1 (11.0) \0.001 62.2 (10.9) 60.2 (10.8) 0.05
CRT, lm 435.0 (126.0) 497.0 (151.0) \0.001 430.0 (128.0) 509.0 (153.0) \0.001
Age, years 62.4 (9.5) 63.6 (8.7) ns 63.2 (9.0) 62.7 (8.7) ns
Women, % 40 42 ns 45 43 ns
HbA1c, % 7.5 (1.2) 7.8 (1.5) 0.01 7.4 (1.2) 7.6 (1.5) ns
Patients with HbA1c
[8%, %
33 35 ns 33 30 ns
Duration of
diabetes, years
15.7 (9.6) 15.9 (10.2) ns 14.4 (9.7) 16.0 (9.7) ns
Data show mean (standard deviation) unless otherwise indicated
Means were based on weighted averages (weights: patient numbers). Pooled variance for two arms in trial 1 and trial 2 (with
n1 and n2 patients and variances Var1 and Var2, respectively) was calculated using the following formula: (n1 - 1) 9
Var1 ? (n2 - 1) 9 Var2/(n1 ? n2 - 2)
Statistical analyses: for continuous variables, P values were calculated using a t test (independent samples); for dichotomous
variables, P values were calculated using a v2 test
BCVA best-corrected visual acuity, CRT central retinal thickness, HbA1c glycated hemoglobin, ns not signiﬁcant, VEGF
vascular endothelial growth factor
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forward (LOCF)] for patient i. Ranibizumabi
(and ranibizumab ? laseri) is a dichotomous
variable equal to 1 if patient i received
ranibizumab (or combination therapy) and 0 if
patient received laser therapy. b0–b9 are
covariate coefficients. Parameter estimates
were presented for b0–b9.
The model is interpreted as follows. The
predicted mean gain for a patient treated with
laser monotherapy and with a mean baseline
BCVA of 55 letters and a mean baseline CRT of
500 lm is b0 ? b3 9 55 ? b4 9 500. If the patient
receives ranibizumab monotherapy, the mean
gain is b0 ? b1 ? (b3 ? b6) 9 55 ? (b4 ? b7) 9
500. If the patient receives combination
therapy, the mean gain is b0 ? b2 ? (b3 ? b8) 9
55 ? (b4 ? b9) 9 500. The mean gain that this
patient achieves with ranibizumab
monotherapy over laser monotherapy is
b1 ? b6 9 55 ? b7 9 500. The mean gain that
this patient achieves with combination
therapy over laser monotherapy is
b2 ? b8 9 55 ? b9 9 500. To estimate the
relative importance of baseline CRT and BCVA
differences between RESPOND/RESTORE and
VIVID-DME/VISTA-DME, two models were
used: one model with treatment and baseline
BCVA as variables and another with treatment
and baseline CRT as variables.
Step 3: Predicting Gains in BCVA After
Ranibizumab Treatment Using VIVID-DME/
VISTA-DME Mean Baseline Characteristics
Baseline values from the aflibercept arms in
VIVID-DME/VISTA-DME were substituted into
the above model to give an estimate of the
change in BCVA from baseline to month 12 for
ranibizumab monotherapy, assuming that
mean patient characteristics in RESPOND were
similar to those in VIVID-DME/VISTA-DME.
Baseline values from the laser monotherapy
arms in VIVID-DME/VISTA-DME were used to
predict the mean response for patients receiving
this treatment.
Step 4: Indirect Treatment Comparison
The predicted gains in BCVA with ranibizumab
monotherapy and laser monotherapy were used
to compare ranibizumab with aflibercept
indirectly, using a Bucher method [18].
Base Case Model (Model 1) Validation
A number of analyses were conducted to assess
the robustness of the results, which are presented
in the online supplementary material.
Sensitivity Analyses (Models 2–6)
Sensitivity analyses were performed to ensure
that the selection of independent variables was
unbiased.
Full Model (Model 2)
In the first sensitivity analysis, a model was
created that included the trial in which the
patient participated, baseline variables
commonly collected in clinical trials for DME
(BCVA, CRT, age, sex, mean HbA1c level, mean
duration of diabetes) and the interaction terms
between trial, baseline characteristics and
treatment.
Stepwise Selection Model (Model 3)
In the second sensitivity analysis, an automated
backward selection process was used to select
variables based on their significance level.
Selected variables were kept in the model if
their P value was \0.10. The rationale behind
using an automated variable selection process
was to remove potential author bias.
Baseline BCVA 24–73 Letters Model (Model 4)
Patients were eligible for enrolment in
VIVID-DME/VISTA-DME only if their baseline
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BCVA was 24–73 letters. The impact of
analyzing only patients in RESPOND/RESTORE
with a baseline BCVA of 24–73 letters was
assessed.
RESTORE CRT Adjustment Model (Model 5)
In RESTORE, optical coherence tomography
(OCT) was performed at every study visit using
Stratus OCT (Carl Zeiss Meditec, Dublin, CA,
USA), which is a time-domain OCT (TD-OCT).
More recent studies (VIVID-DME/VISTA-DME)
[13] used Cirrus OCT (Carl Zeiss Meditec),
which is a spectral-domain OCT (SD-OCT)
[19]. Because it has been shown that CRT
values can be lower when measured with
TD-OCT than with SD-OCT [20, 21], the
RESTORE baseline CRT measurements were
converted into SD-CRT values using published
data linking Stratus OCT and Cirrus OCT
measurements [20]. Specifically, RESTORE
baseline CRT was increased by a mean of
39 lm [standard deviation (SD): 25] [20].
Baseline BCVA <69 Letters Versus ‡69 Letters
Model (Model 6)
The data from model 1 were subdivided to
examine the predicted differences in BCVA gain
after treatment with ranibizumab in patients
with the average baseline characteristics from
two Protocol T subgroups (patients with a
baseline BCVA of\69 letters versus those with
a baseline BCVA of C69 letters). This predicted
result was compared with that published in
Protocol T, where patients are similarly
subdivided.
Statistical Analyses
Statistical analyses were based on the full
analysis set. Missing values were imputed for
the response variable using the LOCF method.
SAR and JW conducted the analyses
independently. SAR used Stata, version 13.0
(StataCorp LP, College Station, TX, USA), and
JW used SAS version 9.4 (SAS Institute, Cary,
NC, USA).
Compliance with Ethics Guidelines
The RESPOND and RESTORE studies were
conducted in accordance with the Declaration
of Helsinki and were approved by the ethics
committee or institutional review board of each
participating center.
RESULTS
Base Case Model (Model 1)
For all treatments, model 1 showed that higher
baseline BCVA was associated with lower visual
acuity gains at 12 months (P\0.05; Table 3).
The impact of baseline BCVA on BCVA gain did
not significantly differ between laser
monotherapy, ranibizumab monotherapy, and
combination therapy (P = 0.53). Higher CRT
values at baseline were associated with
significantly lower BCVA gains at 12 months
for laser monotherapy (P\0.001; Table 3). This
was not observed for ranibizumab monotherapy
or combination therapy (P = 0.12 and P = 0.49,
respectively).
In the base case model (model 1), the mean
predicted gain with ranibizumab monotherapy
was 8.7 letters (95% CI: 7.0–10.5). The mean
predicted gainwithcombination therapywas also
8.7 letters (95% CI: 6.9–10.6), while there was a
mean predicted loss with laser monotherapy
of -1.1 letters (95% CI: -3.0 to 0.7). The
incremental gain with ranibizumab
monotherapy compared with laser monotherapy
was 9.9 letters (95% CI: 7.3–12.4; Table 4; Fig. 1).
When the non-significant interaction between
baseline BCVA and treatment was removed, the
602 Adv Ther (2016) 33:597–609
Table 3 Coefﬁcient estimations of ranibizumab monotherapy and combination therapy









Baseline BCVA -0.180 (0.077)* -0.245 (0.083)** -0.279 (0.049)*** -0.105 (0.084)
Baseline CRT -0.023 (0.006)*** -0.028 (0.007)*** -0.029 (0.006)*** -0.024 (0.006)***
Ranibizumab monotherapy -6.743 (9.371) -17.379 (16.610) -8.021 (4.018)* -11.277 (9.503)
Ranibizumab ? laser 2.707 (9.469) 15.610 (16.967) -6.472 (3.911) 4.790 (9.653)
Ranibizumab 9 BCVA at baseline -0.010 (0.113) 0.016 (0.118) – 0.059 (0.123)
Ranibizumab ? laser 9
BCVA at baseline
-0.121 (0.116) -0.148 (0.125) – -0.169 (0.129)
Ranibizumab 9 CRT at baseline 0.034 (0.009)*** 0.037 (0.010)*** 0.036 (0.009)*** 0.035 (0.009)***
Ranibizumab ? laser 9
CRT at baseline
0.028 (0.009)** 0.029 (0.010)** 0.032 (0.009)*** 0.029 (0.009)**
Baseline HbA1c – -0.864 (0.714) -0.725 (0.397) –
Baseline age – -0.174 (0.100) -0.218 (0.054)*** –
Mean duration of diabetes – 0.012 (0.093) – –
Sex (= 1 for women) – -1.664 (0.964) – –
Ranibizumab 9 HbA1c at baseline – 0.865 (0.997) – –
Ranibizumab ? laser 9
HbA1c at baseline
– -0.350 (1.013) – –
Ranibizumab 9 age at baseline – 0.034 (0.138) – –
Ranibizumab ? laser 9
age at baseline
– -0.153 (0.140) – –
Ranibizumab 9 mean
duration of diabetes
– -0.060 (0.131) – –
Ranibizumab ? laser 9
mean duration of diabetes
– 0.055 (0.120) – –
Constant 21.559 (6.252)*** 45.255 (11.705)*** 49.094 (7.104)*** 17.739 (6.279)**
Observations 557 534 534 463
R2 0.143 0.185 0.173 0.157
Adjusted R2 0.130 0.157 0.160 0.142
Adv Ther (2016) 33:597–609 603
incremental gainwith ranibizumabmonotherapy
compared with laser monotherapy was 10.0
letters (95% CI: 7.4–12.5; Table 4).
When the model included baseline BCVA,
treatment and interaction between treatment
and BCVA, but not baseline CRT, the
incremental gain using ranibizumab
monotherapy compared with laser
monotherapy was 7.7 letters (95% CI:
5.3–10.0). When the model included baseline
CRT, treatment and interaction terms, but not
baseline BCVA, the incremental gain using
ranibizumab monotherapy compared with
laser monotherapy was 9.3 letters (95% CI:
6.8–11.9; Table 4).
Sensitivity Analyses
The estimates of the coefficients for the full
model (model 2), the stepwise selection model
(model 3), and the baseline BCVA 24–73 letters
model (model 4) are shown in Table 3.
Table 3 continued









BIC 4233 4067 4056 3451
Standard errors in parentheses
Note: owing to the presence of interaction terms, the coefﬁcients of ranibizumab monotherapy and combination therapy
should not be interpreted as treatment effects
BCVA best-corrected visual acuity, BIC Bayesian information criterion, CRT central retinal thickness, HbA1c glycated
hemoglobin
* P\0.05, ** P\0.01, *** P\0.001
Table 4 Predicted mean gain in BCVA (number of letters) with ranibizumab over laser monotherapy at month 12 if patients
in RESPOND/RESTORE [11, 12] had the same baseline characteristics as patients in VIVID-DME/VISTA-DME [13]
Model Mean difference in number of letters 95% CI
Base case model (model 1) 9.9 7.3–12.4
Model 1 without interaction between baseline BCVA and treatment 10.0 7.4–12.5
Model 1 without baseline CRT 7.7 5.3–10.0
Model 1 without baseline BCVA 9.3 6.8–11.9
Full model (model 2) 10.1 7.4–12.8
Stepwise selection model (model 3) 10.0 7.4–12.6
Baseline BCVA 24–73 letters (model 4) 9.9 7.5–12.4
RESTORE CRT adjustment model (model 5) 9.1 6.7–11.5
First assumption: patients receiving ranibizumab have the same mean baseline characteristics as those on aﬂibercept in
VIVID-DME/VISTA-DME [13]. Second assumption: patients receiving laser monotherapy have the same mean baseline
characteristics as those on laser monotherapy in VIVID-DME/VISTA-DME [13]
BCVA best-corrected visual acuity, CI conﬁdence interval, CRT central retinal thickness
604 Adv Ther (2016) 33:597–609
Using model 2, the predicted incremental
gain in BCVA with ranibizumab over laser
monotherapy was 10.1 letters (95% CI:
7.4–12.8; Table 4). Using model 3, the
predicted gain in BCVA was 10.0 letters (95%
CI: 7.4–12.6). Using model 4, the predicted gain
in BCVA was 9.9 letters (95% CI: 7.5–12.4). Both
model 4 and the base case model (model 1)
produced similar incremental mean gains over
laser monotherapy for ranibizumab
(approximately 10 letters). The predicted gain
from baseline for ranibizumab was slightly
higher in model 4 than in model 1 (9.3 vs. 8.7
letters); however, the loss in vision was slightly
less with laser monotherapy in model 4 than in
model 1 (-0.6 vs. -1.1). Using model 5, when
increasing baseline CRT for patients in
RESTORE by a mean of 39 lm (SD: 25 lm), the
predicted ranibizumab gain over laser
monotherapy decreased to 9.1 letters (95% CI:
6.7–11.5).
In Protocol T, patients with a baseline BCVA
of\69 letters treated with ranibizumab 0.3 mg
gained 5.9 letters more than patients with a
baseline BCVA of C69 letters (14.2 vs. 8.3 letters
gained, a difference of 5.9 letters). Using the
same sub-grouping for RESPOND/RESTORE
data, model 6 predicts a 3.7-letter difference
after ranibizumab 0.5 mg PRN treatment
between patients with a baseline BCVA of
C69 letters and patients with a baseline BCVA
of \69 letters. Therefore, the differences
observed between patients with BCVA of C69
letters and patients with a baseline BCVA of\69
letters are numerically higher for patients
receiving ranibizumab 0.3 mg PRN in Protocol
T than patients receiving 0.5 mg PRN in
RESTORE/RESPOND. Additional research
should investigate if this higher difference was
due to chance or if ranibizumab 0.5 mg PRN
had a bigger effect than ranibizumab 0.3 mg
PRN for patients with low baseline BCVA.
Indirect Treatment Comparisons
Using unadjusted data, the pooled incremental
gain in letters for ranibizumab monotherapy
over laser monotherapy in RESPOND and
RESTORE was 6.6 letters (standard error 1.10)
(Table 5). The BCVA mean gain for aflibercept
monotherapy over laser monotherapy in
VIVID-DME/VISTA-DME [13] was 10.0 letters
(95% CI: 8.3–11.7; Table 5). This compares with
the predicted BCVA gain, using adjusted data,
in ranibizumab monotherapy compared with
laser monotherapy of 9.9 letters (95% CI:
7.3–12.4; see Table 4). Using those estimates,
there was no statistically significant difference
in letters gained at 12 months between
ranibizumab and aflibercept (0.1-letter
difference; 95% CI: -2.9 to 3.2; P = 0.94;
Fig. 2). There was also no statistically
significant difference between the gain with
Fig. 1 Ranibizumab 0.5 mg pro re nata versus laser
monotherapy. Predicted change in BCVA (95%
conﬁdence interval) from baseline to month 12 if patients
in RESPOND [11] and RESTORE [12] had similar
baseline characteristics to those in VIVID-DME/
VISTA-DME [13]. Results are shown after adjusting
baseline characteristics using the pooled aﬂibercept 2.0 mg
every 8 weeks baseline characteristics from VIVID-DME/
VISTA-DME for ranibizumab predictions and pooled
laser monotherapy baseline characteristics from
VIVID-DME/VISTA-DME for laser monotherapy
predictions. BCVA best-corrected visual acuity, CRT
central retinal thickness
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ranibizumab and that with aflibercept in any of
the other models. Model 5 (RESTORE CRT
adjustment model) showed the largest
difference between aflibercept and
ranibizumab, although this was
non-significant (P = 0.54).
DISCUSSION
Our model predicted that, if patients in
RESPOND/RESTORE had similar BCVA and
CRT as in VIVID/VISTA, the incremental letter
gains of ranibizumab 0.5 mg over laser would
have been greater than those observed in
RESTORE/RESPOND. More specifically, the
ranibizumab incremental response to laser
monotherapy would have been greater than
the unadjusted data by a margin of 3.3 letters.
The main driver of this change in response was
the difference in baseline CRT between
RESPOND/RESTORE and VIVID-DME/
VISTA-DME. Baseline CRT also had a higher
impact on outcomes for laser monotherapy
than for ranibizumab. Specifically, if two
patients undergoing laser monotherapy had a
difference of 100 lm in baseline CRT, BCVA
gain would be, on average, 2.3 letters less for the
patient with the higher baseline CRT. A similar
relationship between baseline CRT and laser
Table 5 Incremental number of letters gained with aﬂibercept treatment compared with laser monotherapy in patients
from RESPOND/RESTORE [11, 12] or from VIVID-DME/VISTA-DME [13]
Treatment Incremental number of letters gained (SE)
RESPOND RESTORE
Ranibizumab 7.5 (1.39) 6.8 (0.77)
Laser monotherapy –0.5 (1.58) 0.9 (1.09)
Ranibizumab incremental gain vs. laser monotherapy 8.0 (1.93) 5.9 (1.33)




Aﬂibercept 10.7 (0.80) 10.7 (0.67)
Laser monotherapy 1.2 (0.92) 0.2 (1.01)
Aﬂibercept incremental gain vs. laser monotherapy 9.5 (1.22) 10.5 (1.21)
Pooled aﬂibercept incremental gain vs. laser monotherapy
(pooled VIVID-DME/VISTA-DME)a
10.0 (0.86)
SE standard error of the estimated mean
a Pooled estimates are calculated with inverse-variance weighting methods
Fig. 2 Indirect treatment comparison (95% conﬁdence
interval) between ranibizumab 0.5 mg pro re nata and
aﬂibercept 2.0 mg every 8 weeks. Ranibizumab-predicted
values after adjustment for baseline characteristics were
used in the analysis. BCVA best-corrected visual acuity,
CRT central retinal thickness
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monotherapy was observed in VIVID-DME/
VISTA-DME. Patients receiving laser
monotherapy with a baseline CRT C400 lm
gained 3 more letters than patients with a
baseline CRT \400 lm [22]. Protocol T also
found a substantial impact of CRT at baseline
(P = 0.01) [9]. For instance, patients receiving
aflibercept with a baseline CRT C400 lm gained
5.3 more letters than patients with a baseline
CRT \400 lm and patients receiving
ranibizumab 0.3 mg with a baseline
CRT C400 lm gained 2.3 more letters than
patients with a baseline CRT\400 lm.
The incremental gains in BCVA using
ranibizumab over laser monotherapy ranged
from 9.9 to 10.0 letters across models 1–4,
which used data from RESPOND and
RESTORE, the narrow range showing the
robustness of the base case model results.
Furthermore, additional variables used across
models were not statistically different between
the trials of interest. Across all models, model 5
had the largest impact with a predictive gain of
9.1 letters, while model 4 had the smallest
impact, producing a predictive gain of 9.9
letters. Nevertheless, the value from model 5
remained well above the unadjusted gain of 6.6
letters.
The absolute letter gains at month 12 as well
as the differences in letter gain between
sub-groups (patients with a baseline BCVA of
\69 letters versus those with a baseline BCVA of
C69 letters) are less pronounced in our analyses
than in Protocol T.
The current analysis underlines the
importance of adjusting for key confounders
when comparing clinical trial data. If the
unadjusted results from RESPOND/RESTORE
and VIVID-DME/VISTA-DME are compared in
a naı¨ve indirect treatment comparison,
aflibercept would appear statistically superior
to ranibizumab 0.5 mg PRN. However, this
analysis demonstrates that this statistical
difference is driven by differences in patient
characteristics between trials.
Some remaining unobserved heterogeneity
may exist between studies even after adjusting
for key baseline characteristics. More details on
the study limitations are given in the online
supplementary material.
Two network meta-analyses in DME have
been published [23, 24]. Additional research
could include using the adjusted clinical trials
outcomes of the analysis to update the network
meta-analyses.
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